INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

Core Viewpoint - Immutep Limited is under investigation for potential securities fraud following the discontinuation of its TACTI-004 Phase III study due to a recommendation from the Independent Data Monitoring Committee (IDMC) [1][3]. Group 1: Company Developments - On March 13, 2026, Immutep announced the IDMC's recommendation to discontinue the TACTI-004 Phase III study evaluating eftilagimod alfa in patients with 1st line non-small cell lung cancer after a planned interim futility analysis [3]. - The IDMC concluded that the trial should be halted based on the available safety and efficacy data, leading to an orderly wind down of the study, including patient follow-up and site closure [3]. - Following this announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.27, or 82.44%, closing at $0.48 per ADR on March 13, 2026 [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Immutep investors regarding potential securities fraud or unlawful business practices by the company and its officers and/or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].